In vitro assessment of platelet storage lesion in leucoreduced random donor platelet concentrates (original) (raw)
Related papers
Pharmacognosy Journal
Therefore, an assessment of the efficacy of platelet transfusions can be measured by calculating the CCI and platelet recovery. In addition, the in vivo hemostatic efficacy after PC transfusion can be measured by the level of CD62P expression and the formation of leukocyte-platelet aggregates. This study aims to determine the difference between CD62P expression in nonleucodepleted and ABSTRACT Platelet concentrates (PCs) are blood components transfused in thrombocytopenic patients, including patients with blood malignancies. PCs contain leukocytes, which can pose potential side effects and activate platelets, reducing the efficacy of platelet transfusion. The leucodepletion process can be carried out by filtration to reduce the leukocyte count. This study aims to determine the difference between the CD62P expression of nonleucodepleted and leucodepleted PCs and to determine the difference between the Corrected Count Increment (CCI) of patients transfused with nonleucodepleted and leucodepleted PCs. This analytic observational study with a cross-sectional design was carried out on PCs obtained from platelet-rich plasma (PRP-PC). PCs were transfused into 48 blood malignancy patients, Yogyakarta, consisting of two groups i.e the group transfused with nonleucodepleted PCs (24 patients) and the group transfused with leucodepleted PCs (24 patients). CD62P expression in PCs was measured by flow cytometry method, and the CCI of the patients was calculated based on the CCI formula. The difference between the median CD62P expression and CCI of the two groups was analyzed using the Mann-Whitney Test with a significance of p<0.05. The median CD62P expression of the nonleucodepleted and leucodepleted groups were 34.4% (16.8-94.4%) and 21.7% (6.2-34.0%), respectively. There was a statistically significant difference between the CD62P expression of the two groups (p = 0.00). The group transfused with nonleucodepleted, and leucodepleted PCs showed respective median CCI of 18.8 x 10 9 /L (2.4-94.8 x 10 9 /L) and 14.7 x 10 9 /L (2.4-124.0 x 10 9 /L). There was no statistically significant difference between the CCI of the two groups (p = 0.42). It can be concluded that the CD62P expression in the PCs of the leucodepleted group was significantly lower than those of the nonleucodepleted group and that there was no significant difference between the CCI of both groups.
Vox sanguinis, 2010
The introduction of platelet (PLT) additive solutions (PASs) and pathogen reduction (PR) technologies possibly allow extension of PLT shelf life. It was our aim to compare in vitro quality of leucocyte-reduced PLT concentrates (PCs) stored in various PASs, including PR, with those in plasma during 8 days of storage. The study was performed in four blood centres where each tested four conditions. In paired experiments (n = 12), buffy coat pools were made to which various storage media were added. Plasma served as reference; two centres used InterSol followed by PR (InterSol+PR) and InterSol without PR; T-sol, SSP+ and Composol were also studied. All PCs fulfilled release criteria (pH(37 degrees C)>6.6; swirl present) until Day 8. Marked differences were seen for other parameters, including CD62P expression: 28 +/- 5; 31 +/- 7; and 39 +/- 9% for T-sol, Intersol+PR and without PR, respectively, which were higher as found for Composol (12 +/- 3%), SSP+ (15 +/- 5%) and plasma (15 +/- ...
Leucocyte and platelet derived bioactive substances in stored standard platelet concentrates
European Journal Of Haematology
Adverse reactions to transfusion of allogeneic blood may depend on content of leucocytes and platelets and on storage-time of the erythrocyte suspensions. Therefore, we studied the efficacy of prestorage leucocyte reduction by filtration on total content and extracellular accumulation of histamine, eosinophil cationic protein (ECP), eosinophil protein X (EPX), myeloperoxidase (MPO), plasminogen activator inhibitor type-1 (PAI-1) and interleukin-6 (IL-6) in samples obtained from 5 units of SAGM blood, 7 units of plasma-reduced whole-blood and 6 units of whole-blood before and after filtration, respectively. In addition, we analysed supernatants from the same units after storage at +4 degrees C for 0, 21 and 35 d, respectively. The filtration was performed at room temperature within 2-4 h after donation. The substances were analysed by ELISA and RIA methods and we also analysed the donor plasma levels of the same bioactive substances. The total content of histamine, ECP, EPX, and MPO were 10-70-fold higher in all unfiltered erythrocyte products compared to donor plasma concentrations, while PAI-1 content was 15-20-fold higher only in plasma-reduced whole-blood and whole-blood. Prestorage leucocyte filtration significantly reduced the total histamine, ECP, EPX, MPO and PAI-1 content to levels similar to donor plasma levels in plasma-reduced whole-blood and whole-blood, while PAI-1 was still low in filtered SAGM blood. In addition, the levels of extracellular bioactive substances at d 0 after donation and filtration were within the range of concentrations in donor plasma, and there was no time-dependent accumulation during storage for 35 d at +4 degrees C. IL-6 was not detected in either plasma or samples obtained from the blood bags. These results suggest prestorage leucocyte filtration to deplete leucocyte contents to levels, which prevent the previously shown time-dependent accumulation of leucocyte derived bioactive substances in various erythrocyte suspensions. In addition, the PAI-1 results suggest leucocyte filters to reduce the obligatory platelet content in whole-blood products.
British Journal of Haematology, 1997
Three different separation methods, all using centrifugation, are routinely used to prepare therapeutic platelet concentrates from human donor blood. Platelet concentrates derived from platelet-rich plasma (PRP-PC), buffy coat (BC-PC) and apheresis (AP-PC) were investigated at the end of production, and over an 8 d storage period. Change in platelet surface markers were measured by flow cytometry, using fluorescein-conjugated antibodies to fibrinogen, P-selectin (CD62P), GPIIb-IIIa (CD41), GPIba (CD42b) and GPV (CD42d), and fluorescein-conjugated Annexin V was used to measure expression of anionic phospholipid.
Vox Sanguinis, 1995
Pooled platelet concentrates (PC) prepared by the platelet-rich plasma (PRP) method were filtered with three different filters and stored for 8 days at room temperature. The effect of filtration on leukocyte contamination, platelet concentration, and the in vitro function, morphology, metabolism and activation of platelets were studied. Eight pools of 20 PRP-PC were used, each pool was split into 4 equal volumes; 3 were filtered over a PLSOHF, a PL-IOA and a Bio P10 filter, the 4 served as a control. After filtration, leukocyte counts exceeded 3 x lo5 in none of the pooled PC. Platelet loss induced by filtration was about 17%. During storage, no differences in pH, PC02, and lactate and glucose concentration were found between the filtered and the unfiltered units, nor were any differences observed between filtered and unfiltered pooled PC in aggregation upon stimulation with collagen andor ADP, adhesion capacity to collagen in flowing blood, nucleotide content of the platelets and nucleobase concentration in the plasma, expression of activation-dependent antigens, or platelet morphology as observed by light microscopy and by the swirling effect. Selective removal of B-thromboglobulin (22%) by the PLSOHF filter was observed. Pooled PC prepared by the PRP-method can be filtered and stored for 8 days without detrimental effect on platelet function, metabolism or activation.
Archives of Iranian Medicine, 2015
Background and objectives: Platelet concentrates (PC) are used in thrombocytopenia and inherited or acquired platelet dysfunction disorders. Thus, retaining the platelets quality and function during storage will lead to desirable outcomes in treatment of such patients. Methods: In this study, we evaluated 40 PC bags, prepared by PRP method in IBTO centers. We applied an array of assays, on first, third and fifth days of storage for PC quality control, including swirling, cell counting, bacterial contamination, measurement of CD62P, pH, and platelet aggregation test, to evaluate platelet lesion during storage. Results: All units were negative for bacterial contamination. Swirling was positive for all units on various days; platelet count was in the acceptable range. Measurement of CD62P on fifth day was not significantly higher than third or first day (P > 0.15) (P > 0.05). pH on fifth day was significantly lower than first day (P < 0.01) (P < 0.05). Platelet aggregation with arachidonic acid and ristocetin showed significant decrease on fifth day compared to third day (P < 0.01) (P < 0.05). Conclusions: CD62P associated with other platelet function tests can be used as an activation marker in evaluation of PC functions during storage.